News

Video

ARVO 2024: Protocol AA from the DRCR Retina Network

At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network and the effect of diabetic retinopathy lesion location and severity on the risk for progression in the long term.

At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network and the effect of diabetic retinopathy lesion location and severity on the risk for progression in the long term.

Video Transcript:

Editor's note: The below transcript has been lightly edited for clarity.

Paolo Silva, MD:

So I'm Paulo Antonio Silva. I'm associate professor at Harvard Medical School, and I'm presenting work on behalf of the DRCR Retina Network. So, we looked at the effect of diabetic retinopathy lesion location and severity on the risk for progression long term. This was a post hoc analysis of the DRCR protocol double A, which evaluated the utility of ultra wide field imaging in predicting the risk of progression long-term. But this post-hoc analysis identified is the importance of the peripheral lesions in predicting and more accurately determining the severity of retinopathy present in these eyes, and allowing us to be more accurate in determining the risk of progression long-term. So I think the DRCR double A dataset provides a rich resource for us to be able to evaluate the risk factors for progression. It will also allow us to potentially change our current DR severity scales, and how these will impact the prediction of eyes that are at increased or at a higher risk of worsening long-term. So we're looking at other novel ways to evaluate this dataset, looking at how exact distances, how non-perfusion changes in the eyes, and how these can be used in clinical practice to help our patients reduce the risk of visual loss from diabetic retinopathy.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.